[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657934":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":11,"studyPopulation":11,"armGroups":35,"interventions":60,"overallOfficials":11,"centralContacts":69,"locations":75,"responsibleParty":106,"collaborators":11,"id":108,"slug":109,"hasResults":110,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":11,"eligibilityCriteria":114,"healthyVolunteers":110,"sex":115,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":11,"studyType":121,"phases":122,"briefSummary":124,"conditions":125,"keywords":11,"overallStatus":127,"whyStopped":11,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},{"fullName":5,"class":6},"Fujian Shengdi Pharmaceutical Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Change From Baseline in HbA1c",null,"Baseline, Week 28",[14,16,18,20],{"measure":15,"description":11,"timeFrame":12},"Percentage of Participants Reaching HbA1c \u003C7.0%, ≤6.5%, and \u003C5.7%",{"measure":17,"description":11,"timeFrame":12},"Percent Change From Baseline in Body Weight",{"measure":19,"description":11,"timeFrame":12},"Change From Baseline in Fasting Plasma Glucose",{"measure":21,"description":11,"timeFrame":22},"TEAEs","Baseline, Week 32",{"allocation":24,"interventionModel":25,"interventionModelDescription":26,"primaryPurpose":27,"observationalModel":11,"timePerspective":11,"maskingInfo":28},"RANDOMIZED","PARALLEL","A Phase II, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Clinical Study","TREATMENT",{"masking":29,"maskingDescription":11,"whoMasked":30},"QUADRUPLE",[31,32,33,34],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[36,41,44,47,50,55],{"label":37,"type":38,"description":11,"interventionNames":39},"Treatment group A","EXPERIMENTAL",[40],"Drug: HRS-4729 Injection",{"label":42,"type":38,"description":11,"interventionNames":43},"Treatment group B",[40],{"label":45,"type":38,"description":11,"interventionNames":46},"Treatment group C",[40],{"label":48,"type":38,"description":11,"interventionNames":49},"Treatment group D",[40],{"label":51,"type":52,"description":11,"interventionNames":53},"Mazdutide","ACTIVE_COMPARATOR",[54],"Drug: Mazdutide",{"label":56,"type":57,"description":11,"interventionNames":58},"Placebo","PLACEBO_COMPARATOR",[59],"Drug: Placebo",[61,65,67],{"type":62,"name":63,"description":63,"armGroupLabels":64,"otherNames":11},"DRUG","HRS-4729 Injection",[37,42,45,48],{"type":62,"name":51,"description":51,"armGroupLabels":66,"otherNames":11},[51],{"type":62,"name":56,"description":56,"armGroupLabels":68,"otherNames":11},[56],[70],{"name":71,"role":72,"phone":73,"phoneExt":11,"email":74},"Mengshan Ni, M.D.","CONTACT","+86 0518-81220121","mengshan.ni.mn1@hengrui.com",[76,93],{"facility":77,"status":11,"city":78,"state":79,"zip":80,"country":81,"countryCode":82,"cosmosGeoPoint":83,"geoPoint":88,"contacts":89},"Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology","Wuhan","Hubei","430030","China","CN",{"type":84,"coordinates":85},"Point",[86,87],114.26667,30.58333,{"lat":87,"lon":86},[90],{"name":91,"role":92,"phone":11,"phoneExt":11,"email":11},"Yan Yang","PRINCIPAL_INVESTIGATOR",{"facility":94,"status":11,"city":95,"state":96,"zip":97,"country":81,"countryCode":82,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Tianjin Medical University Chu Hsien-I Memorial Hospital","Tianjin","Tianjin Municipality","300134",{"type":84,"coordinates":99},[100,101],117.17667,39.14222,{"lat":101,"lon":100},[104],{"name":105,"role":92,"phone":11,"phoneExt":11,"email":11},"Liming Chen",{"type":107,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100657934","phase-2-a-study-of-hrs-4729-injection-in-participants-with-type-2-diabetes-100657934",false,"NCT07843862","A Study of HRS-4729 Injection in Participants With Type 2 Diabetes","A Phase II, Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group Clinical Trial Evaluating the Efficacy and Safety of HRS-4729 Injection in Participants With Type 2 Diabetes","Inclusion Criteria:\n\n1. Have Type 2 Diabetes\n2. Treated with diet and exercise alone or with a stable dose of metformin\n3. Have an HbA1c value at screening of ≥7.5% and ≤10.5%\n\nExclusion Criteria:\n\n1. Have uncontrolled hypertension\n2. Have Type 1 Diabetes, or specific types of diabetes\n3. History of acute diabetic complications or severe hypoglycemic events\n4. History of severe chronic diabetic complications, or non-proliferative diabetic retinopathy requiring treatment\n5. History of any condition affecting gastric emptying, long-term use of medications directly affecting gastrointestinal motility, severe gastrointestinal disease, or prior gastrointestinal surgery\n6. History or known history of acute or chronic pancreatitis, or pancreatic injury\n7. History or known history of acute cholecystitis, or symptomatic\u002Ftreatment-requiring gallbladder disease\n8. Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2)","ALL","18 Years","65 Years",{"count":119,"type":120},240,"ESTIMATED","INTERVENTIONAL",[123],"PHASE2","The main purpose of this study is to evaluate the efficacy and safety of HRS-4729 Injection in participants with type 2 diabetes who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin.",[126],"Type 2 Diabetes","NOT_YET_RECRUITING","2026-09-22",{"date":130,"type":131},"2026-09-28","ACTUAL",{"date":133,"type":120},"2026-10",{"date":135,"type":120},"2027-07",{"name":5,"class":6},2]